Patient-centered or 'central' patient: Raising the veil of ignorance over randomization.
作者信息
Basu Anirban
机构信息
Department of Health Services & Pharmaceutical Outcomes Research and Policy Program, University of Washington Seattle, WA, U.S.A.
出版信息
Stat Med. 2012 Nov 10;31(25):3057-9; discussion 3066-7. doi: 10.1002/sim.5398.
Abstract
摘要
相似文献
1
Patient-centered or 'central' patient: Raising the veil of ignorance over randomization.以患者为中心或“核心”患者：揭开随机化的无知面纱。
Stat Med. 2012 Nov 10;31(25):3057-9; discussion 3066-7. doi: 10.1002/sim.5398.
2
Commentary: How the debate about comparative effectiveness research should impact the future of clinical trials.述评：关于比较效果研究的争论应该如何影响临床试验的未来。
Stat Med. 2012 Nov 10;31(25):3051-3. doi: 10.1002/sim.5400.
3
Comparative effectiveness research: does one size fit all?比较效果研究：一种方法适合所有人吗？
Stat Med. 2012 Nov 10;31(25):3062-5; discussion 3066-7. doi: 10.1002/sim.5482. Epub 2012 Jul 16.
4
Comments on Lauer's 'How the debate about comparative effectiveness research should impact the future of clinical trials'.关于劳尔《关于比较效果研究的争论应如何影响临床试验的未来》的评论
Stat Med. 2012 Nov 10;31(25):3060-1; discussion 3066-7. doi: 10.1002/sim.5397.
5
Commentary on 'How the debate about comparative effectiveness research (CER) should impact the future of clinical trials' by Michael S. Lauer.对迈克尔·S·劳尔所著《关于比较效果研究（CER）的辩论应如何影响临床试验的未来》的评论
Stat Med. 2012 Nov 10;31(25):3054-6; discussion 3066-7. doi: 10.1002/sim.5399.
6
[Toward a comparative effectiveness policy in Italy].[意大利迈向比较疗效政策]
Epidemiol Prev. 2011 Mar-Apr;35(2):77-9.
7
Real-World Evidence of Treatment Effects: The Useful and the Misleading.治疗效果的真实世界证据：有用的与误导性的。
Clin Pharmacol Ther. 2019 Jul;106(1):43-44. doi: 10.1002/cpt.1405. Epub 2019 Apr 3.
8
The promise of comparative effectiveness research.比较效果研究的前景。
JAMA. 2011 Jan 26;305(4):400-1. doi: 10.1001/jama.2011.12.
9
Infrastructure requirements for secondary data sources in comparative effectiveness research.比较效果研究中二次数据源的基础设施要求。
J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl A):S16-21. doi: 10.18553/jmcp.2011.17.s9-a.S16.
10
The need for deliberate and thorough design and critique of observational comparative effectiveness research.对观察性比较效果研究进行审慎且全面的设计与批判的必要性。
Res Social Adm Pharm. 2018 Nov;14(11):1085-1087. doi: 10.1016/j.sapharm.2018.07.012. Epub 2018 Jul 18.
引用本文的文献
1
Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism.口服抗凝药物治疗静脉血栓栓塞症的主要治疗方案比较的住院出血风险。
Br J Haematol. 2019 Jun;185(5):903-911. doi: 10.1111/bjh.15857. Epub 2019 Mar 28.
本文引用的文献
1
Commentary: How the debate about comparative effectiveness research should impact the future of clinical trials.述评：关于比较效果研究的争论应该如何影响临床试验的未来。
Stat Med. 2012 Nov 10;31(25):3051-3. doi: 10.1002/sim.5400.
2
The impact of comparative effectiveness research on health and health care spending.比较效益研究对健康和医疗保健支出的影响。
J Health Econ. 2011 Jul;30(4):695-706. doi: 10.1016/j.jhealeco.2011.05.012. Epub 2011 Jun 1.
3
Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks.心律失常性心脏性猝死的风险分层：识别障碍
Circulation. 2011 May 31;123(21):2423-30. doi: 10.1161/CIRCULATIONAHA.110.959734.
4
Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care.个体化经济学在比较效果研究及以患者为中心的医疗保健中的应用。
J Health Econ. 2011 May;30(3):549-59. doi: 10.1016/j.jhealeco.2011.03.004. Epub 2011 Apr 23.
5
The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research.比较效益研究的经济学：社会和私人视角及其对比较效益研究中公共投资优先级排序的影响。
Pharmacoeconomics. 2010;28(10):843-53. doi: 10.2165/11539400-000000000-00000.
6
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
7
Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects.谁能对治疗产生反应？确定与治疗效果异质性相关的患者特征。
Med Care. 2010 Jun;48(6 Suppl):S9-16. doi: 10.1097/MLR.0b013e3181d99161.
8
Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program.美国晚期前列腺癌的流行病学近期趋势：来自监测、流行病学和最终结果计划的数据分析。
Urology. 2010 Jun;75(6):1396-404. doi: 10.1016/j.urology.2009.07.1360. Epub 2009 Dec 6.
9
Individualization at the heart of comparative effectiveness research: the time for i-CER has come.个体化是比较效果研究的核心：开展个体化比较效果研究（i-CER）的时机已经到来。
Med Decis Making. 2009 Nov-Dec;29(6):NP9-NP11. doi: 10.1177/0272989X09351586.
10
Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change.缅因州医疗补助计划中一项政策变更后非典型抗精神病药物在精神分裂症治疗中的使用情况
Health Aff (Millwood). 2008 May-Jun;27(3):w185-95. doi: 10.1377/hlthaff.27.3.w185. Epub 2008 Apr 1.
Zotero 插件